CTLA4 and pancreatic ductal adenocarcinoma: Additionally, research has indicated that CD40 agonists can enhance the effectiveness of immune checkpoint inhibitors, such as anti-PD1 and anti-CTLA4, in preclinical models of pancreatic ductal adenocarcinoma (PDAC).